Author Archives: David Melamed, PhD

GAIN Trial Reaches Milestone With 500 Patients Enrolled

Cortexyme has reached a milestone after enrolling 500 patients with mild to moderate Alzheimer’s disease in its ongoing Phase 2/3 GAIN clinical trial testing the company’s investigational treatment COR388 (atuzaginstat). Enrollment for GAIN (NCT03823404) has been open since the second quarter of 2019, with…

FDA to Consider Nuplazid to Treat Dementia-related Psychosis

The U.S. Food and Drug Administration (FDA) has accepted a request by Acadia Pharmaceuticals‘ that  Nuplazid (pimavanserin) be approved for a new indication: the treatment of delusions and hallucinations associated with dementia-related psychosis. The company’s supplemental new drug application, which was submitted in June, was granted…